METRNL and type 2 diabetes mellitus: Additionally, increased [32, 33] or decreased [34–36] serum Metrnl expression levels were reported in various systemic diseases such as inflammatory bowel disease, obstructive sleep apnea syndrome, rheumatoid arthritis, coronary artery disease, type 2 diabetes, and in the early phase of sepsis.